BioMed X and Sanofi are no strangers to the rapidly growing AI drug discovery market.
Source: Shutterstock / metamorworks
…
Chief Executive Officer of French pharmaceutical giant Sanofi, Paul Hudson, Paris, September 8, ... [+] 2021. (Photo by JOEL SAGET / AFP) (Photo by JOEL SAGET/AFP via Getty Images) AFP via Getty Images
On Tuesday, June 13, 2023, a very important press release hit the wire - a major pharmaceutical company announced its plans…
In a press release issued on June 13, Sanofi declared its ambition to lead the charge in embracing artificial intelligence (AI) and data science on an unprecedented scale with the aim of becoming the first pharmaceutical company powered by AI across all its operations.
French drugmaker Sanofi (Euronext: SAN) has placed a strong
emphasis on the adoption of artificial intelligence capabilities
to facilitate its internal operations.
The company is rolling out “plai,” a tool for Sanofi staff
developed with AI platform company Aily Labs.
The app is designed to deliver “real-time, reactive…
Sanofi is rolling out its artificial intelligence app, Plai, as it doubles down on its efforts to incorporate AI throughout its research and development activities.
The app, developed in partnership with Aily Labs, can provide real-time data as well as an “unprecedented 360-degree view across all Sanofi activities,” the company said in a statement Tuesday…
Sanofi - Aventis Groupe Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients Paris, June 13, 2023. Sanofi takes the next step in its company-wide digital transformation and rolls-out plai at scale. plai, Sanofi’s industry-leading app developed with artificial intelligence (AI) platform company Aily Labs, delivers real-time, reactive…
Fortune Connect is a new learning community for the next generation of purpose-driven leaders. We provide you with the tools and allies you need to accelerate your career, enter the C-suite, and have a positive impact on business. Join live events with Fortune 500 leaders and build your network.
Paul Hudson, CEO of French pharma and…
With a presence in Hong Kong and New York, Insilico was founded in 2014 with a mission to invent and deploy artificial intelligence tech for pharma and biotech companies to streamline R&D and ‘transform the way therapeutics and materials are discovered’. Its automated AI platform is targeted at precision medicine with the promise of ‘substantially’…
Head over to our on-demand library to view sessions from VB Transform 2023. Register Here
In an era when biopharma research in drug R&D continues to be costly and slow, and artificial intelligence (AI)-based drug discovery platforms are rapidly growing, Paris-based pharmaceutical leader Sanofi announced its latest massive AI drug discovery deal, this time with…
Chesnot/Getty Images
Sanofi has once again entered into a partnership with an artificial intelligence-based drug development firm - this time with Insilico Medicine – in a deal that could be worth as much as $1.2 billion.
The two companies will utilize Insilico’s AI platform, Pharma.AI, to develop drugs for up to six new targets.
Under…